Mechanism of Inulae flos in the treatment of osteoporosis: an analysis based on network pharmacology

doi:10.12307/2021.297

Abstract

Abstract: BACKGROUND: The treatment of osteoporosis is a major problem that plagues the medical field. In particular, the development and application of new drugs have always been the focus of modern pharmacology and regenerative medicine. As a common medicinal herb, Inulae flos has not been studied for its value in the prevention and treatment of osteoporosis. The relationship between the two is analyzed from the network pharmacology level to provide a certain theoretical basis for new drug development and disease treatment.
OBJECTIVE: To explore the application prospects of Inulae flos in the treatment of osteoporosis by means of network pharmacology.
METHODS: The active ingredients of Inulae flos were screened by TCMSP database. The targets of active ingredients were predicted from TCMSP and Swiss Target Prediction database, and the targets of osteoporosis were predicted by GeneCards database and DrugBank database. Protein-protein interaction network analysis was conducted with String database. Cytoscape software was used to construct a protein-protein interaction network diagram and a drug-component-target-disease network diagram. David database was used for enrichment analysis. Molecular docking prediction was completed using autodock vina software.
RESULTS AND CONCLUSION: There were 19 effective pharmaceutical active ingredients of Inulae flos and 180 potential targets for osteoporosis treatment, such as AKT1, TP53, VEGFA. Quercetin, luteolin, and kaempferol are considered to be the key effective ingredients for the treatment of osteoporosis by Inulae flos. The results of enrichment analysis showed that the therapeutic effect of Inulae flos on osteoporosis may be related to cell proliferation and apoptosis, aging, hormone levels and hypoxic stress and other life processes, and may be directly or indirectly associated with mediating signaling pathways such as FOXO, PI3K-Akt, and hypoxia inducible factor 1. The therapeutic effect of Inulae flos on osteoporosis needs to be verified by more basic experiments. Our research provides new ideas and new methods for follow-up experiments.

Key words: traditional Chinese medicine, Inulae flos, osteoporosis, signaling pathway, quercetin, luteolin, kaempferol, network pharmacology, bioinformatics

CLC Number:

An Yang, Liao Yinan, Xie Chengxin, Li Qinglong, Huang Ge, Jin Xin, Yin Dong. Mechanism of Inulae flos in the treatment of osteoporosis: an analysis based on network pharmacology[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(35): 5662-5669.

Figures/Tables 10

References

[1] COSMAN F, DE BEUR SJ, LEBOFF MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10): 2359-2381.
[2] ASPRAY TJ, HILL TR. Osteoporosis and the ageing skeleton. Subcell Biochem. 2019;91:453-476.
[3] 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[4] BECK BR, DALY RM, SINGH MA, et al. Exercise and Sports Science Australia (ESSA) position statement on exercise prescription for the prevention and management of osteoporosis. J Sci Med Sport. 2017;20(5):438-445.
[5] VANDENBROUCKE A, LUYTEN FP, FLAMAING J, et al. Pharmacological treatment of osteoporosis in the oldest old. Clin Interv Aging. 2017;12: 1065-1077.
[6] MIKAMI Y, MATSUMOTO T, KANO K, et al. Current status of drug therapies for osteoporosis and the search for stem cells adapted for bone regenerative medicine. Anat Sci Int. 2014;89(1):1-10.
[7] XIAO Y, LI K, WANG Z, et al. Pectolinarigenin prevents bone loss in ovariectomized mice and inhibits RANKL-induced osteoclastogenesis via blocking activation of MAPK and NFATc1 signaling. J Cell Physiol. 2019;234(8):13959-13968.
[8] ZHAN Y, LIANG J, TIAN K, et al. Vindoline inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice. Front Pharmacol. 2020;10:1587.
[9] JIN HZ, LEE D, LEE JH, et al. New sesquiterpene dimers from Inula britannica inhibit NF-kappaB activation and NO and TNF-alpha production in LPS-stimulated RAW264.7 cells. Planta Med. 2006;72(1):40-45.
[10] DONG M, HONG T, LIU S, et al. Hepatoprotective effect of the flavonoid fraction isolated from the flower of Inula britannica against D-Galactosamine-induced hepatic injury. Mol Med Rep. 2013;7(6):1919-1923.
[11] HAN M, WEN JK, ZHENG B, et al. Acetylbritannilatone suppresses NO and PGE2 synthesis in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 gene expression. Life Sci. 2004;75(6):675-684.
[12] 李祖浩,王辰宇,王中汉,等.骨质疏松性骨缺损的治疗进展:支架植入与局部药物递送[J].中国组织工程研究,2018,22(18):2939-2945.
[13] RU J, LI P, WANG J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
[14] KIM S, SHOEMAKER BA, BOLTON EE, et al. Finding Potential Multitarget Ligands Using PubChem. Methods Mol Biol. 2018;1825:63-91.
[15] STELZER G, ROSEN N, PLASCHKES I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1.30.1-1.30.33.
[16] WISHART DS, FEUNANG YD, GUO AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D1082.
[17] SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.
[18] SZKLARCZYK D, MORRIS JH, COOK H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362-D368.
[19] TROTT O, OLSON AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461.
[20] HUANG DA W, SHERMAN BT, LEMPICKI RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
[21] KHOSLA S, HOFBAUER LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017; 5(11):898-907.
[22] LEDER BZ. Parathyroid hormone and parathyroid hormone-related protein analogs in osteoporosis therapy. Curr Osteoporos Rep. 2017;15(2): 110-119.
[23] LEVIN VA, JIANG X, KAGAN R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018;29(5):1049-1055.
[24] 国家药典委员会.中华人民共和国药典.一部[S].北京:中国医药科技出版社,2020:339.
[25] YUAN Z, MIN J, ZHAO Y, et al. Quercetin rescued TNF-alpha-induced impairments in bone marrow-derived mesenchymal stem cell osteogenesis and improved osteoporosis in rats. Am J Transl Res. 2018;10(12):4313-4321.
[26] DERAKHSHANIAN H, DJALALI M, DJAZAYERY A, et al. Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate. Can J Physiol Pharmacol. 2013;91(5):380-385.
[27] FARR JN, XU M, WEIVODA MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med. 2017;23(9):1072-1079.
[28] SUH KS, CHON S, CHOI EM. Luteolin alleviates methylglyoxal-induced cytotoxicity in osteoblastic MC3T3-E1 cells. Cytotechnology. 2016;68(6):2539-2552.
[29] KIM TH, JUNG JW, HA BG, et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J Nutr Biochem. 2011;22(1):8-15.
[30] JING Z, WANG C, YANG Q, et al. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. J Cell Physiol. 2019; 234(4):4472-4490.
[31] NOWAK B, MATUSZEWSKA A, NIKODEM A, et al. Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia. Pharmacol Rep. 2017;69(5):1113-1119.
[32] KIM CJ, SHIN SH, KIM BJ, et al. The effects of kaempferol-inhibited autophagy on osteoclast formation. Int J Mol Sci. 2018;19(1):125.
[33] SHARMA AR, NAM JS. Kaempferol stimulates WNT/β-catenin signaling pathway to induce differentiation of osteoblasts. J Nutr Biochem. 2019;74:108228.
[34] WONG SK, CHIN KY, IMA-NIRWANA S. The osteoprotective effects of kaempferol: the evidence from in vivo and in vitro studies. Drug Des Devel Ther. 2019;13:3497-3514.
[35] KOMORI T. Cell death in chondrocytes, osteoblasts, and osteocytes. Int J Mol Sci. 2016; 17(12):2045.
[36] BOYLE WJ, SIMONET WS, LACEY DL. Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-342.
[37] RAISZ LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318-3325.
[38] LANE NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194 (2 Suppl):S3-S11.
[39] DOMAZETOVIC V, MARCUCCI G, IANTOMASI T, et al. Oxidative stress in bone remodeling: role of antioxidants. Clin Cases Miner Bone Metab. 2017;14(2):209-216.
[40] XI JC, ZANG HY, GUO LX, et al. The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis. J Recept Signal Transduct Res. 2015;35(6):640-645.
[41] ZHU J, TANG Y, WU Q, et al. HIF-1α facilitates osteocyte-mediated osteoclastogenesis by activating JAK2/STAT3 pathway in vitro. J Cell Physiol. 2019;234(11):21182-21192.
[42] SHAW AT, GRAVALLESE EM. Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol. 2016;49:2-10.
[43] LOCANTORE P, DEL GATTO V, GELLI S, et al. The interplay between immune system and microbiota in osteoporosis. Mediators Inflamm. 2020;2020:3686749.
[44] ALONSO-PÉREZ A, FRANCO-TREPAT E, GUILLÁN-FRESCO M, et al. Role of Toll-Like Receptor 4 on Osteoblast Metabolism and Function. Front Physiol. 2018;9:504.
[45] CHUNG HY, LEE EK, CHOI YJ, et al. Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. J Dent Res. 2011;90(7):830-840.
[46] KOUSTENI S. FoxOs: Unifying links between oxidative stress and skeletal homeostasis. Curr Osteoporos Rep. 2011;9(2):60-66.
[47] MA X, SU P, YIN C, et al. The roles of FoxO transcription factors in regulation of bone cells function. Int J Mol Sci. 2020;21(3):692.
[48] CHEN G, GOEDDEL DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573): 1634-1635.
[49] ZHA L, HE L, LIANG Y, et al. TNF-α contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation. Biomed Pharmacother. 2018;102:369-374.